A statement released earlier today by Warburg Research about Fresenius (ETR:FRE) bumps the target price to 73.40EUR
- Updated: September 15, 2016
Fresenius (ETR:FRE) had its price target raised to 73EUR by Warburg Research in a report issued Thursday September 15 2016. The increased target price implies a potential upside of 0.04% based on the company’s last stock close price.
Previously on 9/13/2016, BNP PARIBAS released a statement for Fresenius(ETR:FRE) bumped the target price from 0.00EUR to 78.00EUR. At the time, this suggested an upside of 0.13%.
Boasting a price of 70.37EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. With the last stock price up 0.00% from the two hundred day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. The company has recorded a 50-day average of 0.00EUR and 200-day average of 0.00EUR. 0 shares of FRE traded, from ann average trading volume of 0
Recent Performance Chart:
With a market cap of 0.0 EUR, Fresenius has a PE of 0 with a 52 week low of 0.00EUR and a 52 week high of 0.00EUR.
Brief Synopsis On Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, and clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.